English English
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Education

Updates on Three Ongoing Clinical Trials on Adults with Severe Hemophilia B

Conference Coverage

Steven W. Pipe, MD

Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People With Hemophilia A

Conference Coverage

Benjamin J. Samelson Jones, MD, PhD

Hemophilia Gene Therapy — Readying for Clinical Care: Webinar Series

Interactive Webinars

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Conference Coverage

Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Conference Coverage

 Anna Sternberg, PhD

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Conference Coverage

Guy Young, MD

Improvements in Health-Related Quality of Life in Adults With Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

Conference Coverage

Steven W. Pipe, MD

Stable Hemostatic Correction and Improved Hemophilia-Related Quality of Life: Final Analysis from the Pivotal Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec

Conference Coverage

Steven W. Pipe, MD

Delivery of CRISPR/Cas9 mRNA LNPs to Repair a Small Deletion in FVIII Gene in Hemophilia A Mice

Conference Coverage

Chun-Yu Chen, PhD

Stabilin-2 Promoter Modulates the Immune Response to FVIII After Lentiviral Vector Delivery in Hemophilic Mice

Conference Coverage

Antonia Follenzi, MD, PhD

A Factor VIII Variant With Elimination of the N-glycosylation Site at 2118 Reduced Anti-FVIII Immune Responses in Gene Therapy Treated Hemophilia A Mice

Conference Coverage

Carol H. Miao, MD

Using the World Federation of Haemophilia Gene Therapy Registry for the Long-term Follow-up of Haemophilia Patients Treated with Gene Therapy

Conference Coverage

Barbara A. Konkle, MD

Impact of Valoctocogene Roxaparvovec Gene Transfer for Severe Haemophilia A on Health-related Quality of Life

Conference Coverage

Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

Dose Selection and Study Design for B-LIEVE, A Phase 1/2 Dose Confirmation Clinical Trial of FLT180A Gene Therapy for Patients with Hemophilia B

Conference Coverage

Pratima Chowdary, MRCP, FRCPath

Final Analysis From the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-state Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderately Severe Hemophilia B

Conference Coverage

Wolfgang Miesbach, MD

Efficacy and Safety of Valoctocogene Roxaparvovec Gene Transfer for Severe Haemophilia A: Results From the GENEr8-1 Two-Year Analysis

Conference Coverage

Steven W. Pipe, MD

Breaking Transgene Tolerance via Immunosuppression

Conference Coverage

Valder R. Arruda, MD, PhD

AAV Integration Summary and Implications

Conference Coverage

Frederic D. Bushman, PhD

Relationship Between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Conference Coverage

Steven W. Pipe, MD

Bleeding Data Across Baseline FIX Expression Levels in People With Hemophilia B: An Analysis Using the ‘Factor Expression Study

Conference Coverage

Steven W. Pipe, MD

Targeting Sinusoial Endothelium

Conference Coverage

Valder R. Arruda, MD, PhD

Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated With Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

Conference Coverage

Steven W. Pipe, MD

Factor IX Expression Within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients With Severe Hemophilia B: Long-term Follow-up Study of the B-Amaze Program

Conference Coverage

Pratima Chowdary, MRCP, FRCPath

Gene Therapy as a Global Solution

Podcasts

Presented by Daniel Hart, BSc, MBChB, MRCP, FRCPath, PhD and Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

 

Subcategories

Interactive Webinars

Expert of the Month Interviews

Back To Top
Image

Please enable the javascript to submit this form

About

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL